This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved three clinical studies testing PrimeVax Immuno-Oncology’s investigational approach using dendritic cells and dengue virus for cancer treatment. The investigational new drug (IND) application is for patients with melanoma (skin cancer) who have failed prior immune checkpoint inhibitors. Hospital…
Conditions
Conditions
NantKwest Launches Phase 1 Trial to Assess Investigational Cell Therapy for B-cell Lymphomas
This post was originally published on this site NantKwest is launching the first-in-human Phase 1 clinical trial assessing the effects of its investigational CD19 t-haNK cell therapy in people with locally advanced B-cell lymphoma. The trial follows the U.S. Food and Drug Administration‘s approval of NantKwest’s investigational new drug (IND) application for the therapy. Natural…
Adding Darzalex to a Velcade-Revlimid Combo Boosts Cancer Disappearance in Newly Diagnosed Multiple Myeloma, Phase 2 Trial Shows
This post was originally published on this site Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing complete cancer disappearance, according to top-line results of a Phase 2 clinical trial. The open-label GRIFFIN study (NCT02874742) includes 223 patients eligible for high-dose chemotherapy…
Collaborative Project Aims to Improve Care for Advanced Ovarian Cancer Patients
This post was originally published on this site A new collaborative project seeks to help ovarian cancer programs better understand and remove impediments to optimal care for patients with advanced epithelial disease. Called “Barriers to Quality Care in Ovarian Cancer,” the effort will be led by the Association of Community Cancer Centers (ACCC), along with AstraZeneca…
Video Series Tackles Prostate Cancer and ADT Use in Doctor-Patient Format
This post was originally published on this site CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called “ADT in Prostate Cancer: Managing Cardiovascular Risk,” the nine-episode series features Andy Rochester, a prostate cancer survivor, discussing his experiences with Susan F.…
Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows
This post was originally published on this site The small molecule inhibitor SM07883, being developed by Samumed, can effectively prevent tau protein toxic accumulation, and tau-mediated neuroinflammation in mice, data from preclinical studies show. As tau-associated mechanisms are implicated in Alzheimer’s disease, these findings suggest that SM07883 may represent a new strategy for the treatment…
Combining Breast, Lung Cancer Therapies Could Overcome Treatment Resistance
This post was originally published on this site Combining Ibrance (palbociclib), a treatment for advanced breast cancer, with the lung cancer medicine crizotinib is more effective against human cancer cells in the laboratory than either drug alone, scientists have found. The researchers say the findings suggest the combination could be used to overcome treatment resistance in some…
First Melanoma Patient Dosed with Syntrix’ SX-682 in Combo with Keytruda in Phase 1/2 Trial
This post was originally published on this site Syntrix Pharmaceuticals has dosed the first patient in an ongoing Phase 1/2 clinical trial testing its experimental therapy SX-682 in combination with Keytruda (pembrolizumab) as a treatment for advanced melanoma, the company announced. The open-label trial (NCT03161431) is being conducted at the Massachusetts General Hospital Cancer Center and…
PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows
This post was originally published on this site PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a second generation fluorine-labeled small molecule that…
Triumvira Cleared to Begin Clinical Testing of TAC01-CD19 in B-cell Lymphomas
This post was originally published on this site Triumvira Immunulogics is launching a Phase 1/2 clinical trial to test its T-cell therapy candidate, TAC01-CD19, in patients with B-cell lymphoma across the U.S. and Canada, the company announced. The TACTIC-19 trial (NCT03880279), set to begin in a few months, comes after the U.S Food and Drug…
MMRF Launches ‘Immune Atlas’ Aiming for Tailored Myeloma Treatments
This post was originally published on this site To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative. Called Immune Atlas, the pilot aims to establish a “gold standard” immune profiling platform for multiple myeloma research studies, and to produce the kind of…
UPMC, Helomics Join to Develop Predictive Models of Ovarian Cancer Outcomes
This post was originally published on this site Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as a way to improve the treatment decision process for ovarian cancer. Despite the advances made to improve diagnosis…